Tallimustine API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Tallimustine API 115308-98-0?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Tallimustine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Tallimustine
- Synonyms:
- Cas Number:
- 115308-98-0
- DrugBank number:
- DB15466
- Unique Ingredient Identifier:
- 71193OXG6S
General Description:
Tallimustine, identified by CAS number 115308-98-0, is a notable compound with significant therapeutic applications. Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA. It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as , which have a favourable cytotoxicity/myelotoxicity ratio. Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.
Indications:
This drug is primarily indicated for: Tallimustine was being investigated for its use in treating tumors. Derivatives of tallimustine with similar DNA binding ability and reduced myelotoxicity are being investigated for their antitumor activity. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Tallimustine functions by: Tallimustine binds to the minor groove of DNA while avoiding targets like glutathione. Currently, the mechanism of DNA minor groove binding agents is poorly understood. Though, they may act by directly inhibiting the interaction of protein and DNA. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Tallimustine is categorized under the following therapeutic classes: Alkylating Drugs, Amino Acids, Peptides, and Proteins, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Hydrocarbons, Halogenated, Mustard Compounds, Noxae, Peptides, Toxic Actions. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Tallimustine is a type of Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
